MS
11
2
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis
A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response
Robotics for Mobility Rehabilitation in MS
Blood Flow Restriction Training in Multiple Sclerosis
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects